Dublin, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027" report to their offering. Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue. This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including: - HIV Co-infection - HBV Co-infection - HCV co-infection Likely downstream events associated with chronic HCV infection include: - Cirrhosis of the liver - Hepatocellular carcinoma - Excess mortality associated with liver disease / decompensated liver function Key Topics Covered: 1. Introduction 2. Cause of the Disease 3. Risk Factors & Prevention 4. Diagnosis of the Disease 5. Variation by Geography/Ethnicity 6. Disease Prognosis & Clinical Course 7. Key comorbid conditions/Features associated with the disease 8. Methodology for quantification of patient numbers 9. Top-line prevalence for Chronic Hepatitis C 10. Genotype of HCV infection in Chronic Hepatitis C patients 10.1 Predominant Genotype 11. Main route of infection for Chronic HCV patients 12. Major viral co-infection in Chronic HCV patients 13. Access to healthcare for CHCV patients 14. Events and outcomes for CHCV patients 15. Abbreviations used in the report 16. Patient-Based Offering 17. Online Pricing Data and Platforms 18. References 19. Appendix For more information about this report visit http://www.researchandmarkets.com/research/qf..._hepatitis
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs
